Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel How to cite this article: Cury-Martins J, Eris APM, Abdalla CMZ, Silva GB, Moura VPT, Sanches JA. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. 2020;95:221-37. , ☆☆ ☆☆ Study conducted at the Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Jade Cury-Martins Adriana Pessoa Mendes Eris Cristina Martinez Zugaib Abdalla Giselle de Barros Silva Veronica Paula Torel de Moura Jose Antonio Sanches About the authors

Abstract

With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.

KEYWORDS
Antineoplastic agents; Antineoplastic agents, immunological; Dermatology; Drug-related side effects and adverse reactions; Medical oncology; Molecular targeted therapy

Sociedade Brasileira de Dermatologia Av. Rio Branco, 39 18. and., 20090-003 Rio de Janeiro RJ, Tel./Fax: +55 21 2253-6747 - Rio de Janeiro - RJ - Brazil
E-mail: revista@sbd.org.br